Nasdaq, S&P 500 Futures Rise: Microsoft Lifts AI Mood, Meta Sinks, Investors Brace For Apple, Amazon And PCE – Why MU, IBRX, CAPR, SBUX Are In Focus
U.S. stock futures were higher in early Thursday trade as investors digested tech earnings, fresh military action in the Middle East, an increasingly divided Federal Reserve and crucial inflation data due later today. Microsoft and Meta earnings highlighted that AI infrastructure spending will continue at an enormous pace. However, investors cheered Microsoft’s reassurance on its $35.8B capex efficiency, and punished Meta’s elevated FY26 capex outlook.
How this was made
The 30-second read
Why it matters
Traders are likely to reprice AI infrastructure spending durability based on Microsoft’s capex efficiency reassurance and Meta’s elevated outlook, while also positioning for Apple’s after-close earnings and PCE later today.
Market read
The most tradable signals are same-session reactions to Microsoft and Meta earnings, plus guidance/approval-driven catalysts in SBUX, IBRX, and CAPR, with macro risk from Fed uncertainty and PCE later today.
What to watch
The article flags Apple memory sourcing pressure and PCE timing, both of which can dominate single-stock moves regardless of company-specific earnings narratives.
Background
The piece is a pre-market US futures wrap that ties tech earnings commentary to AI capex expectations, while also flagging Fed policy division and upcoming inflation data.
Ticker impact
Microsoft shares surged over 7% premarket after Azure strength and CFO Amy Hood said capex can be dialed back if demand shifts.
Likely continued upside bias into the open, with volatility if guidance details disappoint.
The article cites a same-session premarket move tied to a specific capex-efficiency reassurance, which typically sustains momentum but can fade if follow-through is weak.
Meta shares fell about 8% premarket despite strong revenue, as investors were unconvinced by AI investment returns and 2027 spending visibility.
Downside pressure likely persists, especially if management commentary is interpreted as longer payback.
The article links the premarket drop to a concrete mismatch between revenue strength and AI capex return timing, plus limited 2027 visibility.
Amazon edged higher premarket ahead of earnings, with investors focused on AWS growth, cloud margins, and AI-related capex.
Direction depends on AWS margin and capex commentary; expect elevated volatility around the report.
The article provides a clear near-term catalyst (earnings imminence) and specific watch items, but no printed guidance yet.
Apple reports after the close with investors watching iPhone demand and AI strategy amid reports of lawmakers pressuring memory sourcing from China.
Post-close reaction likely hinges on iPhone demand signals and any response to sourcing pressure; volatility expected.
The article flags political/sourcing pressure as a watch item but does not state Apple’s actual guidance or actions.
ImmunityBio rose over 3% premarket after the UAE approved ANKTIVA for bladder cancer and metastatic lung cancer.
Near-term upside bias with momentum risk if details on uptake or commercialization are limited.
A specific regulatory approval is a primary catalyst and is tied to an immediate premarket move.
Capricor Therapeutics rose on retail radar after an FDA advisory panel voted 9-3 against effectiveness of its DMD cardiomyopathy treatment.
Downside or high volatility likely, especially if analysts interpret the vote as reducing approval probability.
The article cites a concrete advisory outcome (9-3 against effectiveness), which is typically market-moving for biotech into subsequent FDA decisions.
Starbucks rose over 4% premarket after boosting full-year operating margin guidance under CEO Brian Niccol’s turnaround strategy.
Likely continued strength into the open, with follow-through depending on whether the guidance implies durable demand and cost control.
A same-session guidance increase is a concrete decision point that traders can reprice immediately.
Micron is listed among chip stocks in focus as Samsung forecasts AI-driven memory shortages could persist through 2028.
Limited single-name edge; any move would likely track broader memory sentiment rather than Micron-specific catalysts.
The only disclosed fact is a sector-level forecast, and Micron is not described with its own earnings, guidance, or regulatory event.
Market effects
AI infrastructure capex remains the dominant read-through, with memory shortage duration (to 2028) supporting the broader semiconductor complex narrative.
US futures modestly higher, suggesting a broadly constructive open despite geopolitical risk headlines.
Middle East strike risk and Fed policy uncertainty can spill into global risk assets and tech-duration valuations.
Counterpoint
Meta’s selloff may be over-discounting near-term AI monetization, while Microsoft’s capex flexibility could be interpreted as demand uncertainty rather than confidence.
Key entities
- companyMicrosoft
Azure quarter strength and CFO reassurance on capex efficiency and ability to dial back GPU/CPU purchases.
- companyMeta Platforms
Strong revenue but weaker investor confidence on AI investment returns and limited 2027 spending visibility.
- companyImmunityBio
UAE approval of ANKTIVA for bladder cancer and metastatic lung cancer.
- companyCapricor Therapeutics
FDA advisory panel vote 9-3 against effectiveness of deramiocel for DMD cardiomyopathy.
- companyStarbucks
Raised full-year operating margin guidance under CEO Brian Niccol’s turnaround strategy.
